Table 1.
Sites of oligoprogressive disease.
| Authors | Driver Mutation |
Design | n | CNS | (%) | Lung | (%) | Lymph Node | (%) | Bone | (%) | Adrenal Gland | (%) | Liver | (%) | Other | (%) | Ref | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yu et al. | EGFR m+ | retro | 18 | 3 | (17) | 14 | (78) | 8 | (44) | 4 | (22) | 1 | (6) | 1 | spleen | (6) | [6] | ||
| Weickhardt et al. | ALK rearrange. EGFR m+ | retro | 25 | 13 | (52) | 7 | (28) | 2 | (8) | 7 | (28) | 2 | (8) | 1 | (4) | [7] | |||
| Qiu et al. | EGFR m+ | retro | 46 | 24 | (52) | 16 | (35) | 6 | (13) | [8] | |||||||||
| Chan et al. | EGFR m+ | retro | 46 | 5 | (11) | 18 | (39) | 2 | (4) | 3 | (7) | 1 | (2) | 1 | pancreas | (2) | [9] | ||
| Rossi et al. | EGFR m+ | retro | 30 | 8 | (27) | 9 | (30) | 8 | (27) | 11 | (36) | 1 | (3) | [10] | |||||
| Santarpia et al. | EGFR m+ | retro | 36 | 9 | (25) | 11 | (31) | 9 | (25) | 5 | (14) | 2 | (6) | [11] | |||||
| Weiss et al. | EGFR m+ at least 6 months without PD | P2 | 25 | 2 | (8) | 15 | (60) | 7 | (28) | 4 | (16) | [12] | |||||||
| Xu et al. | EGFR m+ | retro | 206 | 124 | (60) | 40 | (19) | 9 | (4) | 86 | (42) | 35 | (17) | 18 | (9) | 11 | chest wall, intestine |
(5) | [13] |
| Kagawa et al. | NSCLC m+ or WT | retro | 10 | 1 | (10) | 6 | (60) | 1 | (10) | 1 | (10) | 1 | gall bladder | (10) | [14] |
CNS: central nervous system; NSCLC: non-small cell lung cancer; m+: mutation; P2: phase II study; PD: progression disease; retro: retrospective study; WT: wild type.